Biogen and Denali report Phase IIb LUMA trial data for Parkinson’s

Biogen and Denali Therapeutics have reported data from the Phase IIb LUMA study evaluating BIIB122 for early-stage Parkinson’s disease. Patients received either BIIB122 or a placebo for 48 to 144 weeks. The trial included 648 patients aged 30 to 80 years with early-stage Parkinson’s disease. Credit: R Photography Background / Shutterstock.com. Biogen and Denali Therapeutics have reported data from the Phase IIb LUMA study evaluating their investigational leucine-rich repeat kinase 2 (LRRK2) inhibitor, BIIB122 (DNL151), for early-stage Parkinson’s disease. The multi-centre, global, double-blind, placebo-controlled, randomised trial included 648 patients aged 30 to 80 years with early-stage Parkinson’s disease, with or…

Source: Clinical Trials Arena